Five Cheap Healthcare Stocks With Hedge Fund Support
When it comes to the risk-reward ratio, there are very few sectors which can match up to healthcare.
Array Technologies Inc. (ARRY)
Market is closed
News
- First
- << Previous
- 91 - 100
- Next >>
Billionaires James Flynn, David Abrams, Among the Elite Investors Buying These 4 Stocks Last Week
Individual investors might find hedge fund investing quite expensive, considering the 2-and-2o fee structure most hedge funds employ.
Buffett, Starboard Among the Elite Investors to Disclose New Moves
The deadline for the current round of 13F filings, for the quarterly period that ended December 31, is February 15.
Why Are These Stocks Trending Today?
It's Wednesday and the S&P 500 futures are still firmly in the green in pre-market trading despite the fact that the Federal Reserve is set to raise rates in its FOMC meeting for the first time in over...
Is Array Biopharma Inc (ARRY) a Good Stock To Buy?
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track more than 700 prominent money managers and analyze their quarterly...
Redmile Group Continues To Agressively Buy Shares Of This Biotech
In a recent filing with the SEC, Jeremy Green's Redmile Group, which has been consistently accumulating shares of Array Biopharma Inc (NASDAQ:ARRY) for the past seven quarters, revealed that it has yet...
Redmile Group Fortifies Position In Array Biopharma Inc (ARRY); Broadwood Capital Boosts Stake In STAAR Surgical Company (STAA)
Jeremy Green, the manager of Redmile Group, is still bullish on Array Biopharma Inc (NASDAQ:ARRY) having further increased his holding of the stock.
Redmile Group Is Putting More Money Into Array BioPharma Inc. (ARRY)
Jeremy Green’s Redmile Group has just acquired more shares of Array BioPharma Inc. (NASDAQ:ARRY). In a Form 4 filed with the U.S.
One Of Mark Lampert's Small-Cap Biotech Picks Has Returned 84% This Year And It's Not Done Yet
Mark Lampert’s Biotechnology Value Fund recently filed its 13F with the U.S. Securities and Exchange Commission for the reporting period of March 31.
Should You Buy Optimer Pharmaceuticals, Inc. (OPTR)?
At the moment, there are plenty of metrics investors can use to track their holdings. Two of the most under-the-radar are hedge fund and insider trading interest.
- First
- << Previous
- 91 - 100
- Next >>
Billionaire Hedge Funds
